ANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL
4CPS-184
THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW
4CPS-183
PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING
4CPS-182
DESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
4CPS-181
ELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS
4CPS-180
SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE
4CPS-179
REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH.
4CPS-178
EFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA
4CPS-177
LONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE?
4CPS-176
USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE
4CPS-175
EFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS.
4CPS-174
NASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS
4CPS-173
PRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
4CPS-172
IMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING
4CPS-171
FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB
